Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progesterone to Prevent Postpartum Smoking Relapse
NCT04783857Phase 4Recruiting
- Sponsor
- University of Minnesota
- Start
- Apr 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of progesterone in Tobacco Use Disorder (TUD) (2 arms), sponsored by University of Minnesota. Primary endpoints: Smoking abstinence at 6 months and Child health assessed as smoke exposure and acute infant health at 6 months. Started Apr 2022; status: recruiting.
02
Drugs
progesterone
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04783857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783857.